-
1
-
-
0023076232
-
Human leukocyte 5-lipoxygenase: an enzyme possessing dual enzymatic activities and a multicomponent regulatory system
-
Samuelsson B, Rouzer CA, Matsumoto T. Human leukocyte 5-lipoxygenase: an enzyme possessing dual enzymatic activities and a multicomponent regulatory system. Adv Prostaglandin Thromboxane Leukot Res 1987;17A:1-11.
-
(1987)
Adv Prostaglandin Thromboxane Leukot Res
, vol.17 A
, pp. 1-11
-
-
Samuelsson, B.1
Rouzer, C.A.2
Matsumoto, T.3
-
2
-
-
46749115524
-
Leukotrienes, antileukotrienes and asthma
-
Montuschi P. Leukotrienes, antileukotrienes and asthma. Mini Rev Med Chem 2008;8:647-56.
-
(2008)
Mini Rev Med Chem
, vol.8
, pp. 647-656
-
-
Montuschi, P.1
-
3
-
-
33750102847
-
Therapeutic options for 5-lipoxygenase inhibitors
-
Werz O, Steinhilber D. Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol Ther 2006;112:701-18.
-
(2006)
Pharmacol Ther
, vol.112
, pp. 701-718
-
-
Werz, O.1
Steinhilber, D.2
-
4
-
-
67649861052
-
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
-
Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet 2009;41:783-92.
-
(2009)
Nat Genet
, vol.41
, pp. 783-792
-
-
Chen, Y.1
Hu, Y.2
Zhang, H.3
Peng, C.4
Li, S.5
-
5
-
-
78651453239
-
The structure of human 5-lipoxygenase
-
Gilbert NC, Bartlett SG, Waight MT, Neau DB, Boeglin WE, Brash AR et al. The structure of human 5-lipoxygenase. Science 2011;331:217-9.
-
(2011)
Science
, vol.331
, pp. 217-219
-
-
Gilbert, N.C.1
Bartlett, S.G.2
Waight, M.T.3
Neau, D.B.4
Boeglin, W.E.5
Brash, A.R.6
-
6
-
-
0028824733
-
Arachidonate 5-lipoxygenase
-
Radmark O. Arachidonate 5-lipoxygenase. J Lipid Mediat Cell Signal 1995;12:171-84.
-
(1995)
J Lipid Mediat Cell Signal
, vol.12
, pp. 171-184
-
-
Radmark, O.1
-
8
-
-
0030835266
-
5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice
-
Irvin CG, Tu YP, Sheller JR, Funk CD. 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. Am J Physiol 1997;272:L1053-8.
-
(1997)
Am J Physiol
, vol.272
-
-
Irvin, C.G.1
Tu, Y.P.2
Sheller, J.R.3
Funk, C.D.4
-
9
-
-
17444440118
-
Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice
-
Griffiths RJ, Smith MA, Roach ML, Stock JL, Stam EJ, Milici AJ et al. Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice. J Exp Med 1997;185:1123-9.
-
(1997)
J Exp Med
, vol.185
, pp. 1123-1129
-
-
Griffiths, R.J.1
Smith, M.A.2
Roach, M.L.3
Stock, J.L.4
Stam, E.J.5
Milici, A.J.6
-
10
-
-
0033523672
-
"Scaffold-Hopping" by topological pharmacophore search: a contribution to virtual screening
-
Schneider G, Neidhart W, Giller T, Schmid G. "Scaffold-Hopping" by topological pharmacophore search: a contribution to virtual screening. Angew Chem Int Ed Engl 1999;38:2894-6.
-
(1999)
Angew Chem Int Ed Engl
, vol.38
, pp. 2894-2896
-
-
Schneider, G.1
Neidhart, W.2
Giller, T.3
Schmid, G.4
-
11
-
-
66149130697
-
2-ABT-S-oxide detoxification by glutathione S-transferases A1-1, M1-1 and P1-1: implications for toxicity associated with zileuton
-
Joshi EM, Heasley BH, Macdonald TL. 2-ABT-S-oxide detoxification by glutathione S-transferases A1-1, M1-1 and P1-1: implications for toxicity associated with zileuton. Xenobiotica 2009;39:197-204.
-
(2009)
Xenobiotica
, vol.39
, pp. 197-204
-
-
Joshi, E.M.1
Heasley, B.H.2
Macdonald, T.L.3
-
12
-
-
0028791822
-
The pharmacokinetics of zileuton in healthy young and elderly volunteers
-
Braeckman RA, Granneman GR, Locke CS, Machinist JM, Cavannaugh JH, Awni WM. The pharmacokinetics of zileuton in healthy young and elderly volunteers. Clin Pharmacokinet 1995;29(Suppl. 2):42-8.
-
(1995)
Clin Pharmacokinet
, vol.29
, Issue.SUPPL. 2
, pp. 42-48
-
-
Braeckman, R.A.1
Granneman, G.R.2
Locke, C.S.3
Machinist, J.M.4
Cavannaugh, J.H.5
Awni, W.M.6
-
13
-
-
33947369029
-
Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease
-
Berger W, De Chandt MT, Cairns CB. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int J Clin Pract 2007;61:663-76.
-
(2007)
Int J Clin Pract
, vol.61
, pp. 663-676
-
-
Berger, W.1
De Chandt, M.T.2
Cairns, C.B.3
-
14
-
-
84890807582
-
-
http://crtx.com/docs/zyflo_cr_pi.pdf/June 2013
-
-
-
-
15
-
-
77953642757
-
Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome
-
Tardif JC, L'Allier PL, Ibrahim R, Gregoire JC, Nozza A, Cossette M et al. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging 2010;3:298-307.
-
(2010)
Circ Cardiovasc Imaging
, vol.3
, pp. 298-307
-
-
Tardif, J.C.1
L'Allier, P.L.2
Ibrahim, R.3
Gregoire, J.C.4
Nozza, A.5
Cossette, M.6
-
16
-
-
84890789835
-
-
BIOL-B380 Pacifichem 2010, International Chemical Congress of Pacific Basin Societies, Honolulu, HI, United States, 15-20 December, American Chemical Society, Washington, DC, 2010.
-
Taub R. Treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) in patients with established atherosclerosis. Pacifichem 2010, International Chemical Congress of Pacific Basin Societies, Honolulu, HI, United States, 15-20 December, 2010, American Chemical Society, Washington, DC, 2010;BIOL-380.
-
(2010)
Treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) in patients with established atherosclerosis
-
-
Taub, R.1
-
17
-
-
77955901408
-
The discovery of setileuton, a potent and selective 5-lipoxygenase inhibitor
-
Ducharme Y, Blouin M, Brideau C, Châteauneuf A, Gareau Y, Grimm EL et al. The discovery of setileuton, a potent and selective 5-lipoxygenase inhibitor. ACS Med Chem Lett 2010;1:170-4.
-
(2010)
ACS Med Chem Lett
, vol.1
, pp. 170-174
-
-
Ducharme, Y.1
Blouin, M.2
Brideau, C.3
Châteauneuf, A.4
Gareau, Y.5
Grimm, E.L.6
-
18
-
-
82955198481
-
The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma
-
Wasfi YS, Villaran C, de Tilleghem Cle B, Smugar SS, Hanley WD, Reiss TF et al. The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma. Respir Med 2012;106:34-46.
-
(2012)
Respir Med
, vol.106
, pp. 34-46
-
-
Wasfi, Y.S.1
Villaran, C.2
de Tilleghem Cle, B.3
Smugar, S.S.4
Hanley, W.D.5
Reiss, T.F.6
-
19
-
-
79151482943
-
MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease
-
Bernstein JA, Liu N, Knorr BA, Smugar SS, Hanley WD, Reiss TF et al. MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease. Respir Med 2011;105:392-401.
-
(2011)
Respir Med
, vol.105
, pp. 392-401
-
-
Bernstein, J.A.1
Liu, N.2
Knorr, B.A.3
Smugar, S.S.4
Hanley, W.D.5
Reiss, T.F.6
-
20
-
-
79955026356
-
Novel cytochrome P450-mediated ring opening of the 1,3,4-oxadiazole in setileuton, a 5-lipoxygenase inhibitor
-
Maciolek CM, Ma B, Menzel K, Laliberte S, Bateman K, Krolikowski P et al. Novel cytochrome P450-mediated ring opening of the 1, 3, 4-oxadiazole in setileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 2011;39:763-70.
-
(2011)
Drug Metab Dispos
, vol.39
, pp. 763-770
-
-
Maciolek, C.M.1
Ma, B.2
Menzel, K.3
Laliberte, S.4
Bateman, K.5
Krolikowski, P.6
-
21
-
-
84890803308
-
-
BIOL-B382 Pacifichem 2010, International Chemical Congress of Pacific Basin Societies, Honolulu, HI, United States, 15-20 December, American Chemical Society, Washington, DC, 2010.
-
Ducharme Y. Discovery and development of potent 5-lipoxygenase inhibitors. Pacifichem 2010, International Chemical Congress of Pacific Basin Societies, Honolulu, HI, United States, 15-20 December 2010, American Chemical Society, Washington, DC, 2010;BIOL-382.
-
(2010)
Discovery and development of potent 5-lipoxygenase inhibitors
-
-
Ducharme, Y.1
-
22
-
-
77953771000
-
Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain
-
Masferrer JL, Zweifel BS, Hardy M, Anderson GD, Dufield D, Cortes-Burgos L et al. Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain. J Pharmacol Exp Ther 2010;334:294-301.
-
(2010)
J Pharmacol Exp Ther
, vol.334
, pp. 294-301
-
-
Masferrer, J.L.1
Zweifel, B.S.2
Hardy, M.3
Anderson, G.D.4
Dufield, D.5
Cortes-Burgos, L.6
-
23
-
-
68549092415
-
CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain
-
Cortes-Burgos LA, Zweifel BS, Settle SL, Pufahl RA, Anderson GD, Hardy MM et al. CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain. Eur J Pharmacol 2009;617:59-67.
-
(2009)
Eur J Pharmacol
, vol.617
, pp. 59-67
-
-
Cortes-Burgos, L.A.1
Zweifel, B.S.2
Settle, S.L.3
Pufahl, R.A.4
Anderson, G.D.5
Hardy, M.M.6
-
24
-
-
77953751021
-
In vitro-in vivo correlation and translation to the clinical outcome for CJ-13,610, a novel inhibitor of 5-lipoxygenase
-
Matthew Hutzler J, Linder CD, Melton RJ, Vincent J, Daniels JS. In vitro-in vivo correlation and translation to the clinical outcome for CJ-13, 610, a novel inhibitor of 5-lipoxygenase. Drug Metab Dispos 2010;38:1113-21.
-
(2010)
Drug Metab Dispos
, vol.38
, pp. 1113-1121
-
-
Matthew Hutzler, J.1
Linder, C.D.2
Melton, R.J.3
Vincent, J.4
Daniels, J.S.5
-
25
-
-
69949138207
-
The use of gastrointestinal intubation studies for controlled release development
-
Sutton SC. The use of gastrointestinal intubation studies for controlled release development. Br J Clin Pharmacol 2009;68:342-54.
-
(2009)
Br J Clin Pharmacol
, vol.68
, pp. 342-354
-
-
Sutton, S.C.1
-
26
-
-
84890785914
-
-
http://clinicaltrials.gov/April 2013
-
(2013)
-
-
-
27
-
-
34848921503
-
A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation
-
Burnett BP, Jia Q, Zhao Y, Levy RM. A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation. J Med Food 2007;10:442-51.
-
(2007)
J Med Food
, vol.10
, pp. 442-451
-
-
Burnett, B.P.1
Jia, Q.2
Zhao, Y.3
Levy, R.M.4
-
28
-
-
79952116933
-
Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee
-
Levy RM, Khokhlov A, Kopenkin S, Bart B, Ermolova T, Kantemirova R et al. Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee. Adv Ther 2010;27:731-42.
-
(2010)
Adv Ther
, vol.27
, pp. 731-742
-
-
Levy, R.M.1
Khokhlov, A.2
Kopenkin, S.3
Bart, B.4
Ermolova, T.5
Kantemirova, R.6
-
29
-
-
84862734518
-
Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series
-
W297-300.
-
Chalasani N, Vuppalanchi R, Navarro V, Fontana R, Bonkovsky H, Barnhart H et al. Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series. Ann Intern Med 2012;156:857-60, W297-300.
-
(2012)
Ann Intern Med
, vol.156
, pp. 857-860
-
-
Chalasani, N.1
Vuppalanchi, R.2
Navarro, V.3
Fontana, R.4
Bonkovsky, H.5
Barnhart, H.6
-
30
-
-
76149142698
-
Zileuton, a new efficient and safe systemic anti-acne drug
-
Zouboulis CC. Zileuton, a new efficient and safe systemic anti-acne drug. Dermatoendocrinology 2009;1:188-92.
-
(2009)
Dermatoendocrinology
, vol.1
, pp. 188-192
-
-
Zouboulis, C.C.1
-
31
-
-
0028289770
-
(6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase
-
Laufer SA, Augustin J, Dannhardt G, Kiefer W. (6, 7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J Med Chem 1994;37:1894-7.
-
(1994)
J Med Chem
, vol.37
, pp. 1894-1897
-
-
Laufer, S.A.1
Augustin, J.2
Dannhardt, G.3
Kiefer, W.4
-
32
-
-
0042388365
-
Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin
-
Fiorucci S, Distrutti E, Mencarelli A, Morelli A, Laufor SA, Cirino G et al. Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin. Br J Pharmacol 2003;139:1351-9.
-
(2003)
Br J Pharmacol
, vol.139
, pp. 1351-1359
-
-
Fiorucci, S.1
Distrutti, E.2
Mencarelli, A.3
Morelli, A.4
Laufor, S.A.5
Cirino, G.6
-
33
-
-
19544368809
-
The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway
-
Boileau C, Pelletier JP, Tardif G, Fahmi H, Laufer S, Lavigne M et al. The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway. Ann Rheum Dis 2005;64:891-8.
-
(2005)
Ann Rheum Dis
, vol.64
, pp. 891-898
-
-
Boileau, C.1
Pelletier, J.P.2
Tardif, G.3
Fahmi, H.4
Laufer, S.5
Lavigne, M.6
-
34
-
-
35348914335
-
The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products
-
Fischer L, Hornig M, Pergola C, Meindl N, Franke L, Tanrikulu Y et al. The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products. Br J Pharmacol 2007;152:471-80.
-
(2007)
Br J Pharmacol
, vol.152
, pp. 471-480
-
-
Fischer, L.1
Hornig, M.2
Pergola, C.3
Meindl, N.4
Franke, L.5
Tanrikulu, Y.6
-
35
-
-
52649119793
-
Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1
-
Koeberle A, Siemoneit U, Buhring U, Northoff H, Laufer S, Albrecht W et al. Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J Pharmacol Exp Ther 2008;326:975-82.
-
(2008)
J Pharmacol Exp Ther
, vol.326
, pp. 975-982
-
-
Koeberle, A.1
Siemoneit, U.2
Buhring, U.3
Northoff, H.4
Laufer, S.5
Albrecht, W.6
-
36
-
-
1242342177
-
Licofelone-clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis
-
Alvaro-Gracia JM. Licofelone-clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology (Oxford) 2004;43(Suppl. 1):i21-5.
-
(2004)
Rheumatology (Oxford)
, vol.43
, Issue.SUPPL. 1
-
-
Alvaro-Gracia, J.M.1
-
37
-
-
44949130852
-
Licofelone: the answer to unmet needs in osteoarthritis therapy?
-
Kulkarni SK, Singh VP. Licofelone: the answer to unmet needs in osteoarthritis therapy? Curr Rheumatol Rep 2008;10:43-8.
-
(2008)
Curr Rheumatol Rep
, vol.10
, pp. 43-48
-
-
Kulkarni, S.K.1
Singh, V.P.2
-
38
-
-
82555168047
-
5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-y lmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor
-
Stock NS, Bain G, Zunic J, Li Y, Ziff J, Roppe J et al. 5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-y lmethoxy)-1H-indol-2-yl]-2, 2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor. J Med Chem 2011;54:8013-29.
-
(2011)
J Med Chem
, vol.54
, pp. 8013-8029
-
-
Stock, N.S.1
Bain, G.2
Zunic, J.3
Li, Y.4
Ziff, J.5
Roppe, J.6
-
39
-
-
77949875056
-
Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP)
-
Bain G, King CD, Rewolinski M, Schaab K, Santini AM, Shapiro D et al. Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP). Clin Pharmacol Ther 2010;87:437-44.
-
(2010)
Clin Pharmacol Ther
, vol.87
, pp. 437-444
-
-
Bain, G.1
King, C.D.2
Rewolinski, M.3
Schaab, K.4
Santini, A.M.5
Shapiro, D.6
-
40
-
-
0027492042
-
Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds
-
Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Muller-Peddinghaus R. Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds. Biochem Pharmacol 1993;45:101-11.
-
(1993)
Biochem Pharmacol
, vol.45
, pp. 101-111
-
-
Hatzelmann, A.1
Fruchtmann, R.2
Mohrs, K.H.3
Raddatz, S.4
Muller-Peddinghaus, R.5
-
41
-
-
18244403498
-
Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial
-
Hakonarson H, Thorvaldsson S, Helgadottir A, Gudbjartsson D, Zink F, Andresdottir M et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 2005;293:2245-56.
-
(2005)
JAMA
, vol.293
, pp. 2245-2256
-
-
Hakonarson, H.1
Thorvaldsson, S.2
Helgadottir, A.3
Gudbjartsson, D.4
Zink, F.5
Andresdottir, M.6
-
42
-
-
79957593701
-
Potent inhibitors of 5-lipoxygenase identified using pseudoreceptors
-
Rödl CB, Tanrikulu Y, Wisniewska JM, Proschak E, Schneider G, Steinhilber D et al. Potent inhibitors of 5-lipoxygenase identified using pseudoreceptors. ChemMedChem 2011;6:1001-5.
-
(2011)
ChemMedChem
, vol.6
, pp. 1001-1005
-
-
Rödl, C.B.1
Tanrikulu, Y.2
Wisniewska, J.M.3
Proschak, E.4
Schneider, G.5
Steinhilber, D.6
-
43
-
-
84863353889
-
Dynamic modeling of human 5-lipoxygenase-inhibitor interactions helps to discover novel inhibitors
-
Wu Y, He C, Gao Y, He S, Liu Y, Lai L. Dynamic modeling of human 5-lipoxygenase-inhibitor interactions helps to discover novel inhibitors. J Med Chem 2012;55:2597-605.
-
(2012)
J Med Chem
, vol.55
, pp. 2597-2605
-
-
Wu, Y.1
He, C.2
Gao, Y.3
He, S.4
Liu, Y.5
Lai, L.6
-
44
-
-
50249152994
-
Homology modeling of 5-lipoxygenase and hints for better inhibitor design
-
Aparoy P, Reddy RN, Guruprasad L, Reddy MR, Reddanna P. Homology modeling of 5-lipoxygenase and hints for better inhibitor design. J Comput Aided Mol Des 2008;22:611-9.
-
(2008)
J Comput Aided Mol Des
, vol.22
, pp. 611-619
-
-
Aparoy, P.1
Reddy, R.N.2
Guruprasad, L.3
Reddy, M.R.4
Reddanna, P.5
-
45
-
-
48749125396
-
Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening
-
Tanrikulu Y, Schneider G. Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening. Nat Rev Drug Discov 2008;7:667-77.
-
(2008)
Nat Rev Drug Discov
, vol.7
, pp. 667-677
-
-
Tanrikulu, Y.1
Schneider, G.2
-
46
-
-
34250164182
-
Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening
-
Franke L, Schwarz O, Muller-Kuhrt L, Hoernig C, Fischer L, George S et al. Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem 2007;50:2640-6.
-
(2007)
J Med Chem
, vol.50
, pp. 2640-2646
-
-
Franke, L.1
Schwarz, O.2
Muller-Kuhrt, L.3
Hoernig, C.4
Fischer, L.5
George, S.6
-
47
-
-
54849408377
-
Scaffold-hopping cascade yields potent inhibitors of 5-lipoxygenase
-
Hofmann B, Franke L, Proschak E, Tanrikulu Y, Schneider P, Steinhilber D et al. Scaffold-hopping cascade yields potent inhibitors of 5-lipoxygenase. ChemMedChem 2008;3:1535-8.
-
(2008)
ChemMedChem
, vol.3
, pp. 1535-1538
-
-
Hofmann, B.1
Franke, L.2
Proschak, E.3
Tanrikulu, Y.4
Schneider, P.5
Steinhilber, D.6
-
48
-
-
64549137075
-
PhAST: pharmacophore alignment search tool
-
Hähnke V, Hofmann B, Grgat T, Proschak E, Steinhilber D, Schneider G. PhAST: pharmacophore alignment search tool. J Comput Chem 2009;30:761-71.
-
(2009)
J Comput Chem
, vol.30
, pp. 761-771
-
-
Hähnke, V.1
Hofmann, B.2
Grgat, T.3
Proschak, E.4
Steinhilber, D.5
Schneider, G.6
-
49
-
-
68049094985
-
Bioactivity-guided mapping and navigation of chemical space
-
Renner S, van Otterlo WA, Dominguez Seoane M, Mocklinghoff S, Hofmann B, Wetzel S et al. Bioactivity-guided mapping and navigation of chemical space. Nat Chem Biol 2009;5:585-92.
-
(2009)
Nat Chem Biol
, vol.5
, pp. 585-592
-
-
Renner, S.1
van Otterlo, W.A.2
Dominguez Seoane, M.3
Mocklinghoff, S.4
Hofmann, B.5
Wetzel, S.6
-
50
-
-
84856883818
-
Dual-target virtual screening by pharmacophore elucidation and molecular shape filtering
-
Moser D, Wisniewska JM, Hahn S, Achenbach J, Buscató E, Klingler F-M et al. Dual-target virtual screening by pharmacophore elucidation and molecular shape filtering. ACS Med Chem Lett 2012;3:155-8.
-
(2012)
ACS Med Chem Lett
, vol.3
, pp. 155-158
-
-
Moser, D.1
Wisniewska, J.M.2
Hahn, S.3
Achenbach, J.4
Buscató, E.5
Klingler, F.-M.6
-
51
-
-
84870236442
-
A comparison of antiasthma drugs between acute and chronic ovalbumin-challenged guinea-pig models of asthma
-
Evans RL, Nials AT, Knowles RG, Kidd EJ, Ford WR, Broadley KJ. A comparison of antiasthma drugs between acute and chronic ovalbumin-challenged guinea-pig models of asthma. Pulm Pharmacol Ther 2012;25:453-64.
-
(2012)
Pulm Pharmacol Ther
, vol.25
, pp. 453-464
-
-
Evans, R.L.1
Nials, A.T.2
Knowles, R.G.3
Kidd, E.J.4
Ford, W.R.5
Broadley, K.J.6
-
52
-
-
84872964202
-
Conversion of pro-inflammatory murine Alox5 into an anti-inflammatory 15S-lipoxygenating enzyme by multiple mutations of sequence determinants
-
Hofheinz K, Kakularam KR, Adel S, Anton M, Polymarasetty A, Reddanna P et al. Conversion of pro-inflammatory murine Alox5 into an anti-inflammatory 15S-lipoxygenating enzyme by multiple mutations of sequence determinants. Arch Biochem Biophys 2012;530:40-7.
-
(2012)
Arch Biochem Biophys
, vol.530
, pp. 40-47
-
-
Hofheinz, K.1
Kakularam, K.R.2
Adel, S.3
Anton, M.4
Polymarasetty, A.5
Reddanna, P.6
-
53
-
-
84877948851
-
Rationally designed multitarget agents against inflammation and pain
-
Hwang SH, Wecksler AT, Wagner K, Hammock BD. Rationally designed multitarget agents against inflammation and pain. Curr Med Chem 2013;20:1783-99.
-
(2013)
Curr Med Chem
, vol.20
, pp. 1783-1799
-
-
Hwang, S.H.1
Wecksler, A.T.2
Wagner, K.3
Hammock, B.D.4
|